Clinical trials: HEPATITIS C VIRUS CHRONIC INFECTION
Hepatitis C, Chronic
Treatment of Chronic Hepatitis C Infection by Ledipasvir/Sofosbuvir in Naïve Children
Chronic hepatitis C virus (HCV) infection represents a crucial health problem in children that greatly influence their quality of life.
- Trial name
- NCT05091008
- Testing
- Ledipasvir-Sofosbuvir 90 Mg-400 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Mansoura University Children Hospital
Chronic Hepatitis C
Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan
Hepatitis C virus (HCV) infection is a global health problem, which may lead to chronic hepatitis, cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC).
- Trial name
- NCT00543244
- Testing
- Pegylated interferon alfa and ribavirin
- Where
- 7 sites in Israel, Taiwan
- Volunteers
- 300 people
- Sponsor
- National Taiwan University Hospital
Hepatitis C, Chronic
Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients
In this study we intend to treat patients with chronic hepatitis C of genotype 2 or 3 having characteristics associated with poor treatment response for additional 12 or 24 weeks beyond the standard treatment of PEG-IFN alpha-2b…
- Trial name
- OPTEX2/3 (NCT00803309)
- Testing
- pegylated interferon alpha-2b, Ribavirin
- Where
- 49 sites in Germany
- Volunteers
- 99 people
- Sponsor
- HepNet Study House, German Liverfoundation
HIV Infections, Hepatitis C
Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Genotype 1 and/or 4
A study concerning viral kinetic with 10 co-infected HIV-HCV patients on treatment with peginterferon alfa-2a + ribavirin o IFN + ribavirin was reported in Conference on Retroviruses and Opportunistic Infections 2002 by Dr.
- Trial name
- NCT00612755
- Testing
- Peginterferon alfa-2a + ribavirin
- Where
- 19 sites in Spain
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Hospital Clinico Universitario San Cecilio
Hepatitis C, Chronic Hepatitis C
Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413)
The objective of this study is to assess the impact of participant care and support on treatment adherence. PegIntron pen and Rebetol will be administered to participants with Hepatitis C Virus (HCV) in accordance with approved…
- Trial name
- @dhere (NCT00704964)
- Testing
- PegIntron, Rebetol
- Volunteers
- 746 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)
A Study to assess the general safety and tolerability of the administration of a 3-dose prime/boost regimen of the MRKAd5 HIV-1 gag vaccine (V520) in subjects with chronic hepatitis C virus infection.
- Trial name
- NCT00857311
- Testing
- MRKAd5 HIV-1 gag vaccine (V520), Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed
- Volunteers
- 17 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)
This study involves treatment with boceprevir or placebo in combination with PegIntron (PEG) + Ribavirin (RBV) (weight-based dosing [WBD]) in previously untreated adult participants with chronic hepatitis C (CHC) genotype 1.
- Trial name
- SPRINT-2 (NCT00705432)
- Testing
- Peginterferon alfa-2b (PEG), Ribavirin (RBV), Boceprevir
- Volunteers
- 1,472 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, HIV
Open Label Study to Evaluate Chronic Hepatitis C Treatment in Latino Subjects With and Without HIV Co-infection
Peginterferon alfa-2a has been approved by the U.S. Food and Drug Administration (FDA) to treat adults with chronic hepatitis C virus (HCV) infection with liver disease who have not been previously treated with interferon-alpha…
- Trial name
- LATHCV (NCT01182298)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C, Chronic
An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis
This prospective observational study will evaluate the efficacy and safety of peginterferon alfa-2a in combination with ribavirin in participants with chronic hepatitis C, including participants with compensated liver cirrhosis…
- Trial name
- STANDART (NCT01609049)
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- 57 sites in Russia, South Korea
- Volunteers
- 1,496 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
The Effects of PegIntron Plus Rebetol in Subjects With Chronic Hepatitis C Not Responding to Pegasys (Study P03833)
This is an uncontrolled, non-randomized, open-label, multinational study designed to evaluate the efficacy and safety of PegIntron plus Rebetol in subjects with chronic hepatitis C.
- Trial name
- NCT00441584
- Testing
- PegIntron (peginterferon alfa-2b), Rebetol (ribavirin)
- Volunteers
- 117 people
- Sponsor
- Merck Sharp & Dohme LLC
Anemia, Neutropenia
Treatment of Anemia and Neutropenia in HIV/HCV Coinfected Patients Treated With Pegylated Interferon and Ribavirin
This study is designed to test two separate strategies for treatment of anemia (low hemoglobin) and neutropenia (low white blood cells) in HIV/HCV coinfected patients who are being treated with pegylated interferon and ribavirin.
- Conditions
- Anemia, Neutropenia, Hepatitis C Virus, HIV Infections
- Trial name
- NCT00194857
- Testing
- erythropoietin, GCSF
- Where
- United States
- Sponsor
- Weill Medical College of Cornell University
Hepatitis C
Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual
Patients with chronic hepatitis genotype 1b, who are intolerant or ineligible to Interferon alfa therapy with or without Ribavirin, will be treated for 24 weeks with Daclatasvir (DCV) Dual regimen (= Daclatasvir + Asunaprevir)…
- Trial name
- NCT01995266
- Testing
- Asunaprevir, Daclatasvir
- Where
- 38 sites in China, South Korea and 1 more
- Volunteers
- 218 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C, Chronic
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
The purpose of this study is to assess the efficacy of a 12-week regimen containing simeprevir, daclatasvir and sofosbuvir in participants with decompensated liver disease (the liver function is insufficient) due to genotype 1 or…
- Trial name
- NCT02262728
- Testing
- Simeprevir, Daclatasvir, Sofosbuvir
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Janssen Research & Development, LLC
Hepatitis C, Chronic
A Study to Evaluate the Safety and Efficacy of Celgosivir and Peginterferon Alfa-2b, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype 1 Infection
The objective of the study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
- Trial name
- NCT00217139
- Testing
- Celgosivir
- Where
- 6 sites in Canada
- Volunteers
- 60 people
- Sponsor
- BioWest Therapeutics Inc
Hepatitis C, Liver Disease
Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
This study will explore the relationship of different DEB025 doses in combination with RBV to pharmacokinetic, pharmacodynamic (i.e.
- Trial name
- NCT01970904
- Testing
- Alisporivir, Ribavirin, Peg-IFNα2a
- Where
- 25 sites in Germany, Poland and 2 more
- Volunteers
- 147 people
- Sponsor
- Debiopharm International SA
Chronic Hepatitis C
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for Patients With Genotype 1 Hepatitis C and IL28B CC Polymorphism
Patients with HCV genotype 1 and IL28B CC Polymorphism who have a rapid virological response to treatment are randomised to either 24 or 48 weeks HCV treatment.
- Trial name
- NCT01441804
- Testing
- Peginterferon alfa2a, Ribavirin
- Where
- 4 sites in China
- Volunteers
- 200 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis C
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC
The purpose of this study is to see which of two doses of PEG (polyethylene glycol) interferon alfa-2b in combination with Ribavirin for 48 weeks is more effective at elimination of hepatitis C.
- Trial name
- NCT00207363
- Testing
- Ribavirin, Peg interferon alfa 2b, induction therapy
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- Brooke Army Medical Center
Chronic Hepatitis C
HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients
A Phase II, Open Label, Multi-Center, Proof-Of-Concept Study determing whether treatment with HDV-Interferon (HDV-IFN), by oral or subcutaneous (injection) routes, and ribavirin results in similar efficacy [Rapid Virologic…
- Trial name
- NCT00703872
- Testing
- Oral HDV-Interferon + ribavarin, Injectable HDV-Interferon + ribavarin
- Where
- India
- Volunteers
- 50 people
- Sponsor
- Hepasome Pharmaceuticals
Hepatitis C, Chronic, Sustained Virological Response
Prediction of Liver-related Outcomes After HCV Cure
Objectives: To develop and validate a predictive model, applicable to daily practice, of liver complications emergence in hepatitis C virus (HCV)-infected patients and advanced fibrosis, who have achieved sustained viral response…
- Conditions
- Hepatitis C, Chronic, Sustained Virological Response, Direct-acting Antivirals, Hepatocellular Carcinoma
- Trial name
- NCT04460157
- Where
- Spain
- Volunteers
- 1,035 people
- Sponsor
- Hospital Universitario de Valme
Hepatitis C, Chronic
Evaluation of HCV Viremia Testing Approaches Among PWID in Georgia
This study will evaluate two novel approaches to improve access to Hepatitis C virus (HCV) confirmatory viremia testing. Both approaches are "Harm reduction site-based (HRS)" because HCV viremia testing will be initiated and test…
- Trial name
- HEAD-Start (NCT03594838)
- Testing
- HCV viremia testing approaches
- Where
- 8 sites in Georgia
- Volunteers
- 1,672 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.